Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 2
1(25.0%)
4Total
N/A(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05319496Not ApplicableCompleted

isCGM With Education and Feedback for Non-Insulin Dependent Type 2 Diabetes

Role: collaborator

NCT03277222Phase 2Terminated

Intranasal Treatment of HIV-associated Neurocognitive Disorders

Role: collaborator

NCT03152396Not ApplicableUnknown

Pharmacist CVD Intervention for Patients With Inflammatory Arthritis

Role: lead

NCT00968994Not ApplicableUnknown

Trial of exSALT SD7™ Compared to Xeroform® Petrolatum Dressing for the Management of Partial Thickness Donor Sites

Role: collaborator

All 4 trials loaded